Myriad Genetics Launches New Universal Plus Panel For Its Foresight Carrier Screen
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics, Inc. (NASDAQ:MYGN) has launched a new Universal Plus Panel for its Foresight Carrier Screen, which includes 39 conditions and screens up to 272 genes associated with serious inherited conditions.
June 04, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics has introduced a new Universal Plus Panel for its Foresight Carrier Screen, enhancing its genetic testing offerings by including 39 conditions and screening up to 272 genes.
The launch of the new Universal Plus Panel is likely to positively impact Myriad Genetics' stock price in the short term as it expands the company's product offerings and strengthens its position in the genetic testing market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100